Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 Jun 6:2024.01.16.575879.
doi: 10.1101/2024.01.16.575879.

Macrophage-induced reduction of bacteriophage density limits the efficacy of in vivo pulmonary phage therapy

Sophia Zborowsky  1   2 , Jérémy Seurat  3   4   2 , Quentin Balacheff  1   5 , Solène Ecomard  1   6   7 , Chau Nguyen Ngoc Minh  1   7 , Marie Titécat  8 , Emma Evrard  1 , Rogelio A Rodriguez-Gonzalez  4   9 , Jacopo Marchi  10 , Joshua S Weitz  3   4   10 , Laurent Debarbieux  1
Affiliations

Macrophage-induced reduction of bacteriophage density limits the efficacy of in vivo pulmonary phage therapy

Sophia Zborowsky et al. bioRxiv. .

Abstract

The rise of antimicrobial resistance has led to renewed interest in evaluating phage therapy. In murine models highly effective treatment of acute pneumonia caused by Pseudomonas aeruginosa relies on the synergistic antibacterial activity of bacteriophages with neutrophils. Here, we show that depletion of alveolar macrophages (AM) shortens the survival of mice without boosting the P. aeruginosa load in the lungs. Unexpectedly, upon bacteriophage treatment, pulmonary levels of P. aeruginosa were significantly lower in AM-depleted than in immunocompetent mice. To explore potential mechanisms underlying the benefit of AM-depletion in treated mice, we developed a mathematical model of phage, bacteria, and innate immune system dynamics. Simulations from the model fitted to data suggest that AM reduce bacteriophage density in the lungs. We experimentally confirmed that the in vivo decay of bacteriophage is faster in immunocompetent compared to AM-depleted animals. These findings demonstrate the involvement of feedback between bacteriophage, bacteria, and the immune system in shaping the outcomes of phage therapy in clinical settings.

Keywords: Antimicrobial resistance; Bacterial infection; Innate immunity; Mathematical model; Pneumonia.

PubMed Disclaimer

Conflict of interest statement

DECLARATION OF INTERESTS The authors declare no competing interests.

Figures

Figure 1.
Figure 1.. Phage therapy in the macrophage depleted host.
(A) Flow cytometry analysis of bronco alveolar lavages (BAL) from mice that were given 96 h before clodronate liposomes (depleted) or empty liposomes (control) by intra-tracheal instillation (n=4 each). Cell debris and doublets were first excluded based on CD45 staining. Among the CD45+ population Ly6G+ was used to gate PMN, in the Ly6G− population, the CD11b− correspond to dendritic cells (DC) and alveoli macrophage (AM). The DCs were gated as F4/80− and CD11c+ low while the AM as F4/80+ and CD11c+ high. AM were significantly depleted (p=0.043), whereas PMN and DC were not affected (Mann-Whitney U test). (B) Survival of acute respiratory infection caused by P. aeruginosa (5 × 106 CFU of strain PAKlumi) of AM-depleted mice (clodronate, n=8) and control mice (n=5), p <0.0001 Mantel-Cox log rank test) in absence of phage treatment (full lines). With phage PAK_P1 (5 × 107 PFU) administered intranasally at 2 h p.i. (dashed lines) in AM-depleted (n=5) and control (EL) (n=6) mice, phage treatment significantly improved their survival (p =0.0058 and 0.0016, Mantel-Cox log rank test, for AM-depleted and control mice, respectively). (C) The colonization kinetics of the bioluminescent strain PAKlumi in the lungs is plotted as mean radiance (p/s/cm2/sr) over time. Groups of mice were infected and treated as in panel B with control (n=6), AM-depleted (n=8), phage-treated control (n=9) and phage treated AM-depleted (n=13). Statistical analysis displays unpaired group comparison (Mann-Whitney U test), with stars indicating: in black comparison of untreated groups between depleted and control, in red comparison of control groups between untreated and phage-treated and in blue comparison of AM-depleted groups between untreated and phage-treated. *p<0.05, **p<0.01, ***p<0.005, ****p<0.001. LOQ, limit of quantification. LOD, limit of detection. (D) Bacterial counts (CFUs in log scale) from lung homogenates taken from mice (same animals as in panel C) 22 h post infection. LOD, limit of detection (p values (Mann-Whitney U test) for between groups comparisons are displayed; ns, not significant).
Figure 2.
Figure 2.. Schematic model of bacteria-phage-macrophage-neutrophils interaction in the lungs.
An immune cell close to the arrow represents its impact on the corresponding process. Created in BioRender.com. A full list of equations and parameterization are found in Text S1.
Figure 3.
Figure 3.. Model of bacteria-phage-macrophage-neutrophils interaction in the lungs.
Individual model predictions and data for 3 mice from each group ranked in columns with corresponding headers. Bacteria are in red, phage in green, alveolar macrophage (AM) in light blue, and lung neutrophils in dark blue. Lines are model-based individual dynamics, dots are bacterial densities, triangles are phage concentrations, crossed squares are lung neutrophils and squares are AM. The light red horizontal dashed lines represents the limit of quantification (LOQ) for bacterial density (LOQ = 5.6 log10 CFUeq/mL), light red circles crossed by this line at their center are below the limit of quantification (BLQ) of bacterial density and light red lines are BLQ of bacterial load model-based predictions (i.e. the discrepancy between data and model cannot be evaluated from this plot in case of BLQ data).
Figure 4.
Figure 4.. Median dynamics with various AM-mediated phage decay rate parameter values after infection and phage treatment.
Dynamics of bacteria (red), phage (green), alveolar macrophage (AM, light blue), and lung neutrophils (dark blue) based on the model and its median parameters (Fig. 2A, Text S1), assuming no interaction between macrophages and phage except AM-mediated decay. Each panel corresponds to the different mice groups according to their immune status: (A) immunocompetent control (i.e. empty liposome), (B) AM-depleted (clodronate). Line widths increase depending on the AM-mediated decay rate (multiplied by the macrophage density): 0,1,2,4,8 and 16 times the phage decay in absence of AM, from the thinnest to the widest line. This number is also indicated above the corresponding median bacteria and phage dynamics. The AM-mediated/natural decay rate value leading to the best model (i.e. 8) is represented by solid lines, while the others are represented by dotted lines. The violin and the dots represent the distribution and values of observed CFUs. The limit of detection (LOD) for CFUs is represented by the light red horizontal dashed line (LOD = 2.4 log10 CFU/mL). For AM-depletion, all the observations were below the LOD.
Figure 5.
Figure 5.. AM-associated phage decay and adsorption inhibition assumption.
(A) Uninfected mice were given clodronate (blue) or empty liposomes (red) by intra-tracheal instillation (n=3–4 each) 4 days prior giving phage PAK_P1 (5 × 107 PFU) at t = 0 h. Lungs were collected at 24, 48, 72 and 96 h and homogenized before plating to determine PFU. Data fitted using a monoexponential decay model in the two different groups, with the colored value indicating the corresponding decay rate above each line. *: <0.05, **: <0.01, ***: <0.001, (Mann-Whitney U test). (B) Uninfected mice were given intranasally PBS (n=2) or phage PAK_P1 (5 × 107 PFU) at t = 0 h (n=6) and broncho alveolar lavage was performed 4 h post-administration to sort and count AM and quantify the amount of phage DNA by qPCR. Median dynamics with various adsorption inhibition parameter values after infection and phage treatment for (C) immunocompetent control (i.e. empty liposome) and (D) AM-depleted mice. Dynamics of bacteria (red), phage (green), alveolar macrophage (AM, light blue), and lung neutrophils (dark blue) based on the model and its median parameters (Fig. 2A, Text S1), assuming phagocytosis rate value from the inference of the data of Fig. 4A. Line widths increase depending on the maximal adsorption inhibition by AM: 0%, 15%, 30% and 60%, from the thinnest to the widest line. The maximal adsorption inhibition value leading to the best model (i.e. 30%) is represented by solid lines, while the others are represented by dotted lines. The violin and dots represent the distribution and values of observations: CFUs in red and PFUs in green. The limit of detection (LOD) for CFUs is represented by the light red horizontal dashed line (LOD = 2.4 log10 CFU/mL) For AM-depletion, all the observations were below the LOD.
Figure 6.
Figure 6.. Inter-individual variability in the dynamics of bacteria, phage, alveolar macrophage and lung neutrophils.
Based on the model (Fig. 2) and its median and variability parameters (Text S1), simulations for 1000 individuals in each group are shown by areas covering interquartile interval (Q1-Q3). Each panel corresponds to the different mice groups according to their immune status and phage treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. WHO, O. (2017). One health. World Health Organ.
    1. Bengtsson-Palme J., Kristiansson E., and Larsson D.G.J. (2018). Environmental factors influencing the development and spread of antibiotic resistance. FEMS Microbiol. Rev. 42, fux053. 10.1093/femsre/fux053. - DOI - PMC - PubMed
    1. Urban-Chmiel R., Marek A., Stępień-Pyśniak D., Wieczorek K., Dec M., Nowaczek A., and Osek J. (2022). Antibiotic Resistance in Bacteria—A Review. Antibiotics 11. 10.3390/antibiotics11081079. - DOI - PMC - PubMed
    1. Murray C.J.L., Ikuta K.S., Sharara F., Swetschinski L., Robles Aguilar G., Gray A., Han C., Bisignano C., Rao P., Wool E., et al. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet 399, 629–655. 10.1016/S0140-6736(21)02724-0. - DOI - PMC - PubMed
    1. Nikaido H. (2009). Multidrug Resistance in Bacteria. Annu. Rev. Biochem. 78, 119–146. 10.1146/annurev.biochem.78.082907.145923. - DOI - PMC - PubMed

Publication types

  NODES
admin 2
twitter 2